6662.TWO BioLASCO Taiwan Co., Ltd.
- Market cap
- TWD 727M
- P/E
- 17.9x
- P/B
- 1.69x
- ROE
- 7.4%
- Dividend yield
- 5.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6662.TWO undervalued?
Graham number6662.TWO trades 15.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioLASCO Taiwan Co., Ltd. fundamental analysis
No fundamental analysis for BioLASCO Taiwan Co., Ltd. yet.
BioLASCO Taiwan Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioLASCO Taiwan Co., Ltd.
BioLASCO Taiwan Co., Ltd. operates an animal breeding center to produce specific pathogen-free laboratory animals in Taiwan and internationally. The company offers lab animals, such as rat, mice, and others, as well as surgical services; and rodents housing, washing solutions, workstations, animal housing and management solutions, lab animal research equipment, clean solution, preclinical imaging system, and experimental equipment. It also offers reagents, including lab anim…
Full company profileBioLASCO Taiwan Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioLASCO Taiwan Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 228M | 236M | 265M | 292M | 263M | 251M |
| Gross Profit | 105M | 104M | 104M | 115M | 105M | 92.1M |
| Operating Income | 53.9M | 49.3M | 50.8M | 55.7M | 48.1M | 35.0M |
| EBITDA | - | 64.2M | 73.9M | 67.6M | 63.1M | 54.9M |
| Net Income | 45.2M | 42.3M | 49.7M | 44.0M | 42.4M | 31.5M |
| EPS | 1.76 | 1.65 | 1.94 | 1.72 | 1.66 | 1.23 |
| Balance Sheet | ||||||
| Total Assets | 574M | 570M | 573M | 613M | 593M | 598M |
| Total Liabilities | 114M | 115M | 112M | 163M | 135M | 170M |
| Shareholders' Equity | 460M | 455M | 461M | 449M | 458M | 427M |
| Cash & Short-term Investments | 201M | 169M | 143M | 107M | 80.7M | 85.6M |
| Cash Flow | ||||||
| Operating Cash Flow | 70.8M | 44.7M | 29.5M | 56.9M | 48.7M | 32.8M |
| Capital Expenditure | 4.36M | 4.27M | 1.63M | 55.9M | 21.7M | 11.7M |
| Free Cash Flow | 66.5M | 40.4M | 27.8M | 931K | 27.1M | 21.1M |
| Ratios | ||||||
| ROE | 9.8% | 9.3% | 10.8% | 9.8% | 9.3% | 7.4% |
| ROA | 7.9% | 7.4% | 8.7% | 7.2% | 7.2% | 5.3% |
| Net Profit Margin | 19.8% | 17.9% | 18.8% | 15.1% | 16.2% | 12.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioLASCO Taiwan Co., Ltd. dividends
- Dividend yield
- 5.28%
- Forward dividend
- 1.55 TWD
- Payout ratio
- 90.6%
- Ex-dividend date
- Aug 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 38.4M | 1.50 | 90.6% |
| 2024 | TWD 42.3M | 1.65 | 96.0% |
| 2023 | TWD 38.4M | 1.50 | 77.2% |
| 2022 | TWD 41.0M | 1.60 | 96.9% |
| 2021 | TWD 51.2M | 2.00 | 113.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1055:1000 on Jul 30, 2018.
Who owns BioLASCO Taiwan Co., Ltd.
- Insiders 46.17%
- Institutions 0.00%
- Public & others 53.83%
- Shares outstanding 25.6M
- Free float 15.8M
BioLASCO Taiwan Co., Ltd. company profile
- Company name
- BioLASCO Taiwan Co., Ltd.
- Ticker
- 6662.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 91
- Fiscal year end
- December
- Address
- No. 316, Chongyang Rd., Taipei, Taiwan, 115
- Phone
- 886 2 2651 8669
- Website
- biolasco.com.tw
About BioLASCO Taiwan Co., Ltd.
BioLASCO Taiwan Co., Ltd. operates an animal breeding center to produce specific pathogen-free laboratory animals in Taiwan and internationally. The company offers lab animals, such as rat, mice, and others, as well as surgical services; and rodents housing, washing solutions, workstations, animal housing and management solutions, lab animal research equipment, clean solution, preclinical imaging system, and experimental equipment. It also offers reagents, including lab animal diagnostic reagent, endotoxin testing system, portable endotoxin testing system, rapid microbial detection, biological indicators, and iReal antibody; and various services, such as animal testing, pathology and toxicology, serological testing, lab animal center management services. BioLASCO Taiwan Co., Ltd. was founded in 1990 and is based in Taipei, Taiwan.
BioLASCO Taiwan Co., Ltd. management
3- Mr. Yong-Hao ChenGeneral Manager
- Chang BeckFinancial Officer & Accounting Officer
- Zhi-Hao ZhangAccounting Supervisor